{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:25:10Z","timestamp":1787775910376,"version":"build-2784847793"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>Prolactinomas are the most common type of functional pituitary tumors. Dopamine agonists is the most important drugs used in prolactinoma,have antagonistic effect with antipsychotic drugs used in schizophrenia. Conversely, dopamine antagonist drugs increase prolactin in patients with simultaneous schizophrenia. In the present case, we report a 29-year-old single male with schizophrenia who treated for 8 years with risperidone and presented with macroprolactinoma. Iatrogenic hyperprolactinemia is a well-known side effect of dopamine antagonist drugs for treatment in a patient with schizophrenia. On the other hand, it appears these drugs have the other side effects, such as drug- induced prolactinoma or boost growth.<\/jats:p>","DOI":"10.4103\/abr.abr_96_20","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T09:39:18Z","timestamp":1598607558000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Schizophrenia and Macroprolactinoma: Is There a Deep Link?"],"prefix":"10.4103","volume":"9","author":[{"given":"Atefeh","family":"Bamarinejad","sequence":"first","affiliation":[{"name":"Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shidrokh","family":"Nasiri","sequence":"additional","affiliation":[{"name":"Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Bamarinejad","sequence":"additional","affiliation":[{"name":"Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rezvan","family":"Salehidoost","sequence":"additional","affiliation":[{"name":"Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe","family":"Zare-Farashbandi","sequence":"additional","affiliation":[{"name":"Clinical Informationist Research Group, Health Information Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"R1-20250805","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R2-20250805","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1590\/2359-3997000000195","article-title":"Incidence and prevalence of clinically relevant pituitary adenomas: Retrospective cohort study in a Health Management Organization in Buenos Aires, Argentina","volume":"60","author":"Day","year":"2016","journal-title":"Arch Endocrinol Metab"},{"key":"R3-20250805","first-page":"288","article-title":"Efficacy and safety of dopamine agonists in psychiatric patients treated with antipsychotics and presenting a macroprolactinoma","volume":"63","author":"Allard","year":"2019","journal-title":"Eur Cong Endocrinol"},{"key":"R4-20250805","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0014-2999(96)00920-X","article-title":"Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum","volume":"321","author":"Inoue","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"R5-20250805","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nrn4005","article-title":"Social cognition in schizophrenia","volume":"16","author":"Green","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"R6-20250805","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/s-2002-36709","article-title":"Hyperprolactinemia: Etiology, diagnosis, and management","volume":"20","author":"Mah","year":"2002","journal-title":"Semin Reprod Med"},{"key":"R7-20250805","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","article-title":"Dopamine as a prolactin (PRL) inhibitor","volume":"22","author":"Ben-Jonathan","year":"2001","journal-title":"Endocr Rev"},{"key":"R8-20250805","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1210\/endo.140.11.7118","article-title":"Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice","volume":"140","author":"Asa","year":"1999","journal-title":"Endocrinology"},{"key":"R9-20250805","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/0269881108091252","article-title":"Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases","volume":"23","author":"Akkaya","year":"2009","journal-title":"J Psychopharmacol"}],"container-title":["Advanced Biomedical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_96_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:45:39Z","timestamp":1787773539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_96_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.4103\/abr.abr_96_20","relation":{},"ISSN":["2277-9175"],"issn-type":[{"value":"2277-9175","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"2020-05-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}